A patient with rheumatoid arthritis presents with increased fatigue, joint pain, and swelling. Laboratory tests show elevated CRP and ESR levels, with positive rheumatoid factor and high ACPA levels. The treatment plan includes methotrexate and prednisone, but due to disease progression, the addition of a biologic agent is being considered. Which nursing intervention is most critical in ensuring the safe administration of the new biologic therapy?

C) Ensure the patient receives appropriate vaccinations before starting the therapy.

A) Educate the patient about the potential side effects of the biologic agent.

B) Monitor the patient's liver function tests regularly.

C) Ensure the patient receives appropriate vaccinations before starting the therapy.

D) Assess the patient's dietary intake to support immune function.

A patient with rheumatoid arthritis presents with increased joint pain, fatigue, and swelling, along with synovitis and early deformities. The patient's lab results show elevated CRP and ESR levels. The healthcare team is considering the addition of a biologic agent to the treatment regimen. Which nursing intervention is most appropriate to prioritize before the initiation of biologic therapy?

B) Assess the patient for any signs of infection, such as fever or sore throat.

A) Educate the patient about the importance of regular exercise to maintain joint function.

B) Assess the patient for any signs of infection, such as fever or sore throat.

C) Encourage the patient to increase fluid intake to prevent dehydration.

D) Monitor the patient's blood pressure and heart rate for any cardiovascular changes.

A patient with rheumatoid arthritis has been started on a TNF-alpha inhibitor and presents with new onset of generalized weakness and shortness of breath on exertion. A chest X-ray reveals bilateral pleural effusions and interstitial markings. What is the most appropriate nursing intervention in response to these findings?

C) Collaborate with the healthcare provider to evaluate the necessity of continuing the TNF-alpha inhibitor.

A) Encourage the patient to increase physical activity to improve respiratory function.

B) Educate the patient on the importance of adhering to the current medication regimen despite new symptoms.

C) Collaborate with the healthcare provider to evaluate the necessity of continuing the TNF-alpha inhibitor.

D) Advise the patient to use over-the-counter medications to manage joint pain and stiffness.

A patient with rheumatoid arthritis has been started on a TNF-alpha inhibitor. During a follow-up visit, she reports generalized weakness and shortness of breath on exertion. A chest X-ray reveals bilateral pleural effusions and interstitial markings. Which nursing intervention is most appropriate to address the patient's current respiratory symptoms?

A) Encourage the patient to perform deep breathing exercises and use incentive spirometry.

B) Suggest the patient increase fluid intake to help with joint lubrication.

C) Advise the patient to engage in regular aerobic exercise to improve lung capacity.

D) Instruct the patient to rest in a supine position to aid breathing.

A patient with rheumatoid arthritis on TNF-alpha inhibitors has been diagnosed with interstitial lung disease. To optimize the patient's treatment plan while minimizing pulmonary complications, which nursing intervention is the most appropriate to prioritize?

A) Educate the patient on the importance of regular pulmonary function tests to monitor lung status.

B) Suggest the patient increase physical activity to improve joint mobility and lung function.

C) Advise the patient to self-monitor for signs of infection and report them immediately.

D) Encourage the patient to continue the current medication regimen until further notice from the healthcare provider.

A patient with rheumatoid arthritis being treated with a TNF-alpha inhibitor presents with new respiratory symptoms. Pulmonary function tests and HRCT confirm interstitial lung disease. What is the most appropriate nursing action in response to the changes in the patient's condition?

B) Educate the patient about the potential need to switch to a non-biologic DMARD and discuss her concerns.

A) Advise the patient to continue the TNF-alpha inhibitor and monitor symptoms.

B) Educate the patient about the potential need to switch to a non-biologic DMARD and discuss her concerns.

C) Instruct the patient to stop all medications immediately and schedule an urgent follow-up with the rheumatologist.

D) Recommend increasing the dose of the TNF-alpha inhibitor to address persistent joint symptoms.

A patient with rheumatoid arthritis and interstitial lung disease presents with increased fatigue, shortness of breath, and new crackles on auscultation. The healthcare team is considering the introduction of intravenous cyclophosphamide. What is the nurse's priority intervention to ensure patient safety prior to starting this medication?

D) Assess the patient's renal function through laboratory tests.

A) Obtain a baseline pulmonary function test.

B) Monitor the patient's blood pressure frequently.

C) Educate the patient about potential gastrointestinal side effects.

D) Assess the patient's renal function through laboratory tests.

A patient with rheumatoid arthritis and interstitial lung disease presents with increased fatigue, shortness of breath, and a dry cough. The healthcare team is considering the introduction of corticosteroids or immunosuppressive agents. As a nurse, which of the following considerations is most critical when preparing the patient for this change in treatment?

C) Ensuring the patient has received vaccinations, as immunosuppressive therapy may increase infection risk.

A) Assessing the patient's understanding of potential side effects associated with corticosteroids.

B) Evaluating the patient's current pulmonary function to establish a baseline before starting new medications.

C) Ensuring the patient has received vaccinations, as immunosuppressive therapy may increase infection risk.

D) Reviewing the patient's dietary intake to recommend increased protein for wound healing support.

A patient with rheumatoid arthritis and interstitial lung disease is on a treatment regimen that includes mycophenolate mofetil. She reports slight improvement in shortness of breath and stable mild anemia, but persistent dry cough. Considering her current status and treatment, which nursing intervention is most appropriate to address her persistent cough while continuing to monitor her overall respiratory function?

B) Advise the patient to use a humidifier at home to alleviate the dry cough.

A) Increase the patient's fluid intake to help thin respiratory secretions.

B) Advise the patient to use a humidifier at home to alleviate the dry cough.

C) Recommend the patient to perform incentive spirometry exercises regularly.

D) Suggest the patient to reduce physical activity to minimize exertion.

A patient with rheumatoid arthritis and interstitial lung disease has been on mycophenolate mofetil for a week and reports slight improvement in shortness of breath but persistent dry cough. As a nurse, which action is most appropriate to prioritize during this follow-up visit?

A) Reassess the patient's oxygen saturation and respiratory rate at rest and after exertion.

B) Increase the frequency of pulmonary rehabilitation sessions to enhance respiratory function.

C) Monitor the patient for signs of mycophenolate mofetil toxicity, including gastrointestinal symptoms.

D) Suggest discontinuing mycophenolate mofetil due to persistent symptoms and consider alternative therapies.

rheumatoid arthritis - Nursing Case Study

Pathophysiology

• Primary mechanism: Autoimmune response - The immune system mistakenly attacks the synovial membrane, leading to inflammation. This inflammation causes synovial cells to proliferate, forming pannus, which erodes cartilage and bone.

• Secondary mechanism: Cytokine production - Pro-inflammatory cytokines like TNF-alpha and IL-6 are released, perpetuating inflammation and joint damage. These cytokines enhance immune cell recruitment, amplifying the destructive process.

• Key complication: Joint deformity - Chronic inflammation and pannus formation result in joint destruction and deformities, significantly impairing mobility and quality of life for affected individuals.

Patient Profile

Demographics:

47-year-old female, office administrator

History:

• Key past medical history: Diagnosed with rheumatoid arthritis 5 years ago, history of hypertension

• Current medications: Methotrexate, Prednisone, Lisinopril

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Increased joint pain and stiffness

• Key symptoms: Swelling in hands and wrists, morning stiffness lasting over an hour, fatigue, and occasional low-grade fever

• Vital signs: Blood pressure 145/90 mmHg, heart rate 92 bpm, respiratory rate 18 breaths per minute, temperature 99.1°F

Section 1

As the patient's condition evolves, the healthcare team observes new complications that require careful clinical reasoning and management. During a routine follow-up, the patient reports an exacerbation of her symptoms, including increased fatigue and difficulty performing daily activities due to worsening joint pain and swelling. The physical examination reveals significant synovitis in the wrists and metacarpophalangeal joints, with noticeable ulnar deviation and early signs of swan-neck deformities in some fingers. These findings suggest a progression of the disease, underscoring the need for further evaluation and adjustment of her treatment plan.

Laboratory tests are conducted to gain a clearer understanding of the patient's current condition. The results indicate elevated inflammatory markers, with a C-reactive protein (CRP) level of 20 mg/L and an erythrocyte sedimentation rate (ESR) of 45 mm/hr, both suggestive of active inflammation. Additionally, the rheumatoid factor (RF) remains positive, and anti-citrullinated protein antibody (ACPA) levels are high, reinforcing the diagnosis of aggressive rheumatoid arthritis. A recent X-ray of the hands shows joint space narrowing and early erosive changes, confirming the radiographic progression of the disease.

These developments prompt the healthcare team to consider modifications to the patient's therapeutic regimen. The current use of methotrexate and prednisone may require reassessment, and the addition of a biologic agent targeting pro-inflammatory cytokines such as TNF-alpha may be necessary to better control the disease activity. The patient is counseled on the potential risks and benefits of introducing biologic therapy, as well as the importance of regular monitoring to prevent further joint damage and preserve function. This decision-making process highlights the need for ongoing clinical vigilance and personalized care in managing chronic conditions like rheumatoid arthritis.

Section 2

Several weeks after the adjustment of the patient's treatment plan to include a TNF-alpha inhibitor, the healthcare team conducts a follow-up evaluation to assess her response to the new intervention. During this visit, the patient reports a modest improvement in joint pain and swelling, although she continues to experience significant morning stiffness lasting over an hour. She also notes a new onset of generalized weakness and shortness of breath on exertion, which she had not experienced prior to the change in medication.

A thorough physical examination reveals stable vital signs with a blood pressure of 125/80 mmHg, heart rate of 88 beats per minute, and respiratory rate of 20 breaths per minute. However, there is decreased breath sounds at the lung bases bilaterally, suggestive of possible pleural involvement. Heart sounds are regular with no murmurs, and there is no peripheral edema. The synovitis in the wrists and fingers shows slight reduction, but the ulnar deviation and swan-neck deformities remain unchanged.

Given the patient's new respiratory symptoms, further diagnostic testing is initiated. A chest X-ray reveals bilateral pleural effusions and interstitial markings that raise suspicion for interstitial lung disease, a potential complication of rheumatoid arthritis and its treatment. Pulmonary function tests are ordered to assess the extent of lung involvement, and a referral to a pulmonologist is made for further evaluation. This development necessitates a careful re-evaluation of the patient's treatment strategy, balancing the benefits of aggressive rheumatoid arthritis management against the potential adverse effects on pulmonary function, underscoring the complexity of managing multi-system complications in rheumatoid arthritis.

Section 3

Following the initial suspicion of interstitial lung disease, the patient undergoes pulmonary function tests, which reveal a restrictive pattern characterized by a reduced total lung capacity and a decreased diffusion capacity for carbon monoxide (DLCO). These findings are consistent with interstitial lung involvement, a known but concerning complication in rheumatoid arthritis patients, particularly those on TNF-alpha inhibitors. The pulmonologist conducts a high-resolution computed tomography (HRCT) scan of the chest, which confirms the presence of ground-glass opacities and reticular patterns in both lungs, further supporting the diagnosis of interstitial lung disease.

In light of these diagnostic results, the healthcare team convenes to discuss the implications for the patient's treatment plan. The modest improvement in joint symptoms must now be weighed against the significant risk of progressive pulmonary involvement. It is determined that while the TNF-alpha inhibitor has provided some relief from articular symptoms, its potential contribution to the patient's pulmonary condition necessitates careful reconsideration. The team explores alternative disease-modifying antirheumatic drugs (DMARDs) that have less pulmonary toxicity, such as switching to a non-biologic DMARD or considering a trial of a different biologic agent with a lower risk of lung complications.

The patient is informed of the findings and the proposed changes to her treatment regimen. She expresses concern about the impact on her quality of life, particularly due to the persistent morning stiffness and the new respiratory symptoms. The healthcare team emphasizes the importance of regular monitoring and follow-up with both rheumatology and pulmonology to manage her condition effectively. This collaborative approach aims to optimize her overall health outcomes, addressing both her rheumatologic and pulmonary needs while minimizing potential side effects. As the patient agrees to the revised treatment plan, the team plans for close follow-up visits to monitor her response and adjust the strategy as needed.

Section 4

Two weeks into the revised treatment plan, the patient returns for a follow-up appointment. During the initial assessment, the nurse notes that the patient appears more fatigued and reports increased shortness of breath, particularly during exertion. She also mentions experiencing a dry cough that has become more frequent. Vital signs reveal a slight tachypnea with a respiratory rate of 22 breaths per minute, and her oxygen saturation on room air is 93%, slightly lower than previous readings. Auscultation of the lungs reveals fine inspiratory crackles, particularly at the lung bases, which were not as prominent in prior assessments.

Given these new symptoms and findings, the healthcare team decides to conduct additional diagnostic tests to evaluate the progression of her interstitial lung disease. A repeat HRCT scan shows an increase in ground-glass opacities and the development of traction bronchiectasis, suggesting a worsening of the pulmonary condition. Concurrently, her laboratory results indicate a mild anemia with a hemoglobin level of 10.5 g/dL, which could contribute to her fatigue. In light of these results, the team must reconsider the current treatment strategy and weigh the potential benefits of introducing corticosteroids or other immunosuppressive agents to address the escalating pulmonary involvement.

The patient's condition prompts a more urgent multidisciplinary discussion to reassess the balance between controlling her rheumatoid arthritis and managing the progression of interstitial lung disease. The team deliberates over the potential introduction of intravenous cyclophosphamide or mycophenolate mofetil, both alternatives with a more favorable pulmonary profile. Meanwhile, the patient is counseled on the importance of pulmonary rehabilitation and lifestyle modifications to optimize her respiratory function and quality of life. This carefully coordinated approach emphasizes the need for vigilant monitoring and flexible adaptation of the treatment plan to mitigate further complications and improve her overall health outcomes.

Section 5

A week after the revised treatment plan, which included the initiation of mycophenolate mofetil, the patient returns to the clinic for a follow-up assessment. During the initial evaluation, the nurse notes that while the patient still experiences fatigue, her shortness of breath has slightly improved, particularly at rest. However, she reports that her dry cough persists with little change. Vital signs reveal a respiratory rate of 20 breaths per minute and an oxygen saturation of 94% on room air, indicating a slight improvement from her previous visit. Auscultation still reveals fine inspiratory crackles at the lung bases, though they are somewhat less pronounced. The patient's hemoglobin level remains stable at 10.5 g/dL, and she continues to exhibit mild anemia.

The healthcare team reviews the new diagnostic results, which include pulmonary function tests revealing a slight improvement in forced vital capacity (FVC), suggesting a positive response to the mycophenolate mofetil. This improvement, although modest, prompts the team to continue with the current immunosuppressive regimen while closely monitoring the patient's respiratory status. Additionally, the patient has been participating in pulmonary rehabilitation, which may be contributing to her improved exertional capacity. She is encouraged to maintain her participation in these sessions and continue implementing lifestyle modifications aimed at enhancing her respiratory function.

As discussions continue among the multidisciplinary team, the focus shifts to maintaining a delicate balance in her treatment to prevent potential new complications. The team remains vigilant for any signs of adverse effects from the medication and is prepared to adjust the treatment plan as necessary. The patient's journey emphasizes the importance of ongoing monitoring and open communication between the patient and healthcare providers to ensure optimal management of both her rheumatoid arthritis and interstitial lung disease.